Pages that link to "Q36970133"

The following pages link to Treatment adherence and long-term outcomes. (Q36970133):

Displaying 29 items.

• Medication adherence in schizophrenia (Q26823655) (← links)
• Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain (Q28266158) (← links)
• Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review (Q33589087) (← links)
• Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results (Q34048194) (← links)
• Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial (Q34660553) (← links)
• Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia (Q35143555) (← links)
• Pharmacogenetics of antipsychotic-induced side effects (Q35237129) (← links)
• Balancing efficacy and safety in treatment with antipsychotics. (Q36970128) (← links)
• Risperidone long-acting injection: a review of its long term safety and efficacy (Q37062563) (← links)
• Psychiatrists' awareness of partial and nonadherence to antipsychotic medication in schizophrenia: results from an Asia-Pacific survey (Q37104411) (← links)
• Adherence to medication in the community: audit cycle of interventions to improve the assessment of adherence (Q37619620) (← links)
• Dosing and switching of paliperidone ER in patients with schizophrenia: recommendations for clinical practice (Q37714573) (← links)
• Practical guidelines on the use of paliperidone palmitate in schizophrenia (Q37982822) (← links)
• Rates and predictors of relapse in first-episode non-affective psychosis: a 3-year longitudinal study in a specialized intervention program (PAFIP). (Q39233956) (← links)
• How do socio-demographic and clinical factors interact with adherence attitude profiles in schizophrenia? A cluster-analytical approach (Q39817602) (← links)
• Effect of a system-oriented intervention on compliance problems in schizophrenia: a pragmatic controlled trial (Q40785183) (← links)
• Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). (Q41899147) (← links)
• Management of antipsychotic treatment discontinuation and interruptions using model-based simulations (Q42149681) (← links)
• The meaning of pharmacological treatment for schizophrenic patients (Q42687191) (← links)
• Safety and efficacy of long-acting injectable risperidone in patients with schizophrenia spectrum disorders: a 6-month open-label trial in Asian patients (Q43107442) (← links)
• Functional recovery results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). (Q43694540) (← links)
• Adherence to treatment and therapeutic strategies in schizophrenic patients: the ADHERE study. (Q45246308) (← links)
• Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients (Q50794479) (← links)
• Commentary: The Impact of Digital Technology on Psychological Treatments and Their Dissemination (Q58697962) (← links)
• Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE) (Q60604241) (← links)
• Switching to paliperidone extended release in patients with schizophrenia dissatisfied with previous olanzapine treatment: Post hoc analysis of an open-label, prospective study (Q64235298) (← links)
• Impact of oral antipsychotic medication adherence on healthcare resource utilization among schizophrenia patients with Medicare coverage (Q87234183) (← links)
• Effectiveness, Adverse Effects and Drug Compliance of Long-Acting Injectable Risperidone in Children and Adolescents (Q88561246) (← links)
• Utilization of somatic healthcare in Croatian patients with schizophrenia spectrum disorder, major depression, PTSD and the general population (Q93112073) (← links)